MacroGenics Inc logo

MGNX - MacroGenics Inc News Story

$17.33 0.7  4.3%

Last Trade - 02/12/21

Sector
Healthcare
Size
Mid Cap
Market Cap £766.4m
Enterprise Value £541.2m
Revenue £87.4m
Position in Universe 2933rd / 7294

MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

Tue 26th October, 2021 9:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211026:nGNE5vhxqp&default-theme=true


ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:
MGNX), a biopharmaceutical company focused on developing and commercializing
innovative monoclonal antibody-based therapeutics for the treatment of cancer,
today announced that the Company will release its financial results for the
third quarter of 2021 after the market closes on Tuesday, November 2, 2021. 
MacroGenics will host a conference call to discuss the financial results and
recent corporate progress on Tuesday, November 2, 2021 at 4:30 pm ET. The
conference call can be accessed by dialing (877) 303-6253 (domestic) or (973)
409-9610 (international) five minutes prior to the start of the call and
providing the Conference ID# 6063045.

The listen-only webcast of the conference call can be accessed under "Events &
Presentations" in the Investor Relations section of the Company's website
at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast
will be available shortly after the conclusion of the call and archived on the
Company's website for 30 days following the call.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and
commercializing innovative monoclonal antibody-based therapeutics for the
treatment of cancer. The Company generates its pipeline of product candidates
primarily from its proprietary suite of next-generation antibody-based
technology platforms, which have applicability across broad therapeutic
domains. The combination of MacroGenics' technology platforms and protein
engineering expertise has allowed the Company to generate promising product
candidates and enter into several strategic collaborations with global
pharmaceutical and biotechnology companies. For more information, please see
the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics
logo are trademarks or registered trademarks of MacroGenics, Inc. 
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.